喉癌保留器官治疗中气管造口依赖的风险分析
本研究回顾性分析了87例接受根治性保器官治疗并接受气管造口的喉癌患者,随访中48例(55%)需永久性气管造口,39例(45%)成功拔管。多因素分析显示,原发放疗(OR 12.857,P < .001)和复发(OR 25.84,P < .001)是永久性气管造口的独立危险因素。
要点
- 原发放疗和肿瘤复发是永久性气管造口的独立危险因素。
- 保器官治疗中气管造口患者约55%最终需永久造口。
- 需关注接受原发放疗或出现复发的患者的气管造口拔管可能性。
核心结论
- 原发根治性放疗和肿瘤复发是喉癌保器官治疗中气管造口依赖的独立危险因素。
研究设计与样本
- 回顾性队列研究,纳入单中心87例接受根治性保器官治疗并在治疗前、中、后接受气管造口的喉癌患者。
主要发现
- 随访期间48例(55%)需永久性气管造口,39例(45%)成功拔管。
- 多因素分析显示原发放疗的OR为12.857(P < .001),复发的OR为25.84(P < .001)。
临床怎么用
- 对接受原发放疗或出现复发的喉癌患者,应提前评估永久性气管造口风险并加强拔管规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A tracheostomy has an enormous negative impact on the patient's quality of life. The purpose of this study is to describe risk factors for permanent tracheostomies in patients undergoing curative organ-preserving treatment of laryngeal cancer. METHODS: The charts of all patients with laryngeal cancer diagnosed at our tertiary referral center were reviewed. Cases receiving a tracheostomy before, during, or after primary organ-preserving treatment were eligible. RESULTS: A total of 87 patients who underwent tracheostomies were enrolled in the present study. During follow-up, 48 patients (55%) required a permanent tracheostomy, whereas 39 patients (45%) were decannulated. Multivariate analysis revealed primary radiotherapy (RT; odds ratio [OR] 12.857; P < .001) and recurrence (OR 25.84; P < .001) as independent factors of permanent tracheostomy. CONCLUSION: This study identifies primary curative RT and tumor relapse as independent risk factors of permanent tracheostomy dependency in patients with laryngeal cancer undergoing a tracheostomy during or after primary curative organ-preserving treatment.
引用
- Anschuetz L, Visini M, Shelan M, et al. Risk analysis for tracheostomy dependency in curatively treated laryngeal cancer with organ preservation. Head Neck. 2018. PMID: 30307670. doi:10.1002/hed.25373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。